CEO and Founding Director of the Terasaki Institute for Biomedical Innovation, also Professor of Bioengineering, Chemical Engineering and Radiology at the University of California-Los Angeles (UCLA)
Dr. Ali Khademhosseini will present his work on integrating engineering and physical science principles with precision medicine through the development of precision biomaterials, ‘smart diagnostic/therapeutic devices, personalized cells and ‘organ on a chip’ systems. These advances help in fulfilling the promise of personalized therapeutics.
As of April 2020, Ali Khademhosseini is now the CEO and Founding Director of the Terasaki Institute for Biomedical Innovation. He is also a Professor of Bioengineering, Chemical Engineering and Radiology at the University of California-Los Angeles (UCLA). He was the Founding Director of the Center for Minimally Invasive Therapeutics at UCLA but is currently on leave with Amazon Web Services (AWS) Inc. as an Amazon Researcher. He joined UCLA as the Levi Knight Chair starting Nov. 2017 from Harvard University where he was a Professor at the Harvard Medical School (HMS) and faculty at the Harvard-MIT’s Division of Health Sciences and Technology (HST), Brigham and Women’s Hospital (BWH) and as well as associate faculty at the Wyss Institute for Biologically Inspired Engineering. At Harvard University, he directed the Biomaterials Innovation Research Center (BIRC) a leading initiative in making engineered biomedical materials. He is recognized as a leader in combining micro- and nano-engineering approaches with advanced biomaterials for regenerative medicine applications. In particular, his laboratory has pioneered numerous technologies and materials for controlling the architecture and function of engineered vascularized tissues. He has authored >650 journal papers (H-index > 128, >61,300 citations) and 70 books/chapters. In addition, he has delivered 300+ invited/keynote lectures. Dr. Khademhosseini’s interdisciplinary research has been recognized by over 60 major national and international awards. He is a recipient of the Presidential Early Career Award for Scientists and Engineers, the highest honor given by the US government for early career investigators. In 2011, he received the Pioneers of Miniaturization Prize from the Royal Society of Chemistry (RSC) for his contribution to microscale tissue engineering and microfluidics. In 2016, he received the Sr. Scientist Award of Tissue Engineering and Regenerative Medicine Society -Americas Chapter (TERMIS-AM) and in 2017 he received the Clemson Award of the Society for Biomaterials. He is a fellow of the American Institute of Medical and Biological Engineering (AIMBE), Biomedical Engineering Society (BMES), Royal Society of Chemistry (RSC), Biomaterials Science and Engineering (FBSE), Materials Research Society (MRS), NANOSMAT Society, and American Association for the Advancement of Science (AAAS). He is also the recipient of the Mustafa Prize ($500,000 prize) as well as a member of the International Academy of Medical and Biological Engineering, Royal Society of Canada and Canadian Academy of Engineering. Currently he serves on the editorial board of numerous leading journals as well as an Associate Editor for ACS Nano. He received his Ph.D. in bioengineering from MIT (2005), and MASc (2001) and BASc (1999) degrees from University of Toronto both in chemical engineering.